Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiatives

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.


Scope

  • Country specific event-driven sales forecasts for the period 2006-15 for the US, Japan, France, Germany, Italy, Spain and the UK
  • Discussion of recent trials and market-shaping future key events
  • Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
  • Case studies evaluating the commercial impact of two developmental agents with blockbuster potential


    • Report Highlights
    Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents.

    The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market.

    The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines.


    Reasons to Purchase

  • Quantify future size and scope of the antithrombotics market and potential for new products
  • Analyze options to expand commercial potential through pursuit of new indications
  • Formulate successful launch strategies in a highly competitive mature market

    • Table of Contents

    Other users found this report page using the following search terms: antithrombotics anticoagulants thrombosis market patent tenecteplase expiry warfarin list clopidogrel drug share antithrombotics

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.